Meta-Analysis of RCTs: GLP-1 Drugs Show Trends but No Significant Limb Benefits in PAD | Research

The takeaway

In a meta-analysis of 5 randomized controlled trials with 25,067 patients, GLP-1 receptor agonists showed non-significant trends toward reduced revascularization (OR 0.87) and amputations (OR 0.82) in PAD.

Not significant
Unlike observational studies, RCT-only analysis found GLP-1 drugs' PAD limb benefits did not reach statistical significance

What the researchers found

In 5 RCTs (25,067 patients), GLP-1 RAs showed non-significant trends for revascularization (OR 0.87, 95% CI 0.73-1.05, p=0.13) and amputations (OR 0.82, 95% CI 0.53-1.27, p=0.37) in PAD patients.

Why it matters

Separating RCT evidence from observational data provides a more accurate picture of GLP-1 drugs' true effects on PAD limb outcomes, tempering earlier enthusiasm while not ruling out benefit.

How the study worked

Systematic review and meta-analysis of randomized controlled trials only (5 studies, 25,067 patients), using Cochrane methodology and random-effects models.

What this study cannot tell us

Only 5 RCTs met criteria. Limited amputation events (224). PAD was not the primary endpoint in most included trials. May be underpowered for limb-specific outcomes.

How to read the evidence

Meta-analysis of RCTs — the highest evidence quality. However, underpowered for limb-specific outcomes since PAD was not the primary endpoint in most trials.

When this study was published

Published in 2025.

The bigger picture

The discrepancy between observational (strongly positive) and RCT (trending positive) evidence highlights the importance of study design when evaluating GLP-1 drug benefits in vascular disease.

Questions still open

Would a dedicated PAD-focused RCT definitively show limb benefits?
Are the observational benefits driven by selection bias or real biological effects?
Should future cardiovascular outcome trials include PAD-specific limb endpoints?

Common questions

Do GLP-1 drugs help with peripheral artery disease?

Observational studies suggest yes, but this analysis of only randomized controlled trials found trends toward benefit that didn't reach statistical significance. The evidence is promising but not conclusive.

Why is this different from other PAD studies?

This analysis only included randomized controlled trials (the gold standard), which showed weaker effects than earlier observational studies. This suggests some of the observed benefits may be due to biases in observational research.

Read the original research

Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis.

Diabetes therapy : research, treatment and education of diabetes and related disorders

View on PubMed ↗Publisher’s paper ↗

Citation

Elliott, Beth; Tomlinson, Ellie; Desai, Nirali; Heald, Adrian; Field, Benjamin C; Heiss, Christian; Whyte, Martin B. (2026). Evaluating the Effects of Glucagon-Like Peptide 1 Receptor Agonists as a Secondary Prevention in Peripheral Arterial Disease: A Meta-Analysis.. Diabetes therapy : research, treatment and education of diabetes and related disorders. https://doi.org/10.1007/s13300-026-01843-x